Atara Biotherapeutics, Inc. (ATRA)
9.48
+1.02
(+12.06%)
USD |
NASDAQ |
Oct 02, 16:00
9.60
+0.12
(+1.27%)
After-Hours: 20:00
Atara Biotherapeutics EPS Diluted (Quarterly) : -0.3216 for June 30, 2026
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -0.3216 |
| March 31, 2026 | -0.2944 |
| December 31, 2025 | -0.465 |
| September 30, 2025 | -0.3172 |
| June 30, 2025 | 0.1939 |
| March 31, 2025 | 3.503 |
| December 31, 2024 | -1.187 |
| September 30, 2024 | -2.934 |
| June 30, 2024 | -3.101 |
| March 31, 2024 | -5.646 |
| December 31, 2023 | -13.98 |
| September 30, 2023 | -16.40 |
| June 30, 2023 | -0.6766 |
| March 31, 2023 | -0.7192 |
| December 31, 2022 | -0.7228 |
| September 30, 2022 | -0.821 |
| June 30, 2022 | 0.1813 |
| March 31, 2022 | -0.8747 |
| December 31, 2021 | -0.9583 |
| September 30, 2021 | -0.9045 |
| June 30, 2021 | -0.9093 |
| March 31, 2021 | -0.8565 |
| December 31, 2020 | -0.9532 |
| September 30, 2020 | -0.9159 |
| June 30, 2020 | -1.140 |
| Date | Value |
|---|---|
| March 31, 2020 | -1.201 |
| December 31, 2019 | -1.361 |
| September 30, 2019 | -1.309 |
| June 30, 2019 | -1.601 |
| March 31, 2019 | -1.436 |
| December 31, 2018 | -43.70 |
| September 30, 2018 | -32.13 |
| June 30, 2018 | -28.66 |
| March 31, 2018 | -26.17 |
| December 31, 2017 | -28.80 |
| September 30, 2017 | -25.51 |
| June 30, 2017 | -23.45 |
| March 31, 2017 | -22.07 |
| December 31, 2016 | -15.75 |
| September 30, 2016 | -22.00 |
| June 30, 2016 | -16.50 |
| March 31, 2016 | -14.50 |
| December 31, 2015 | -18.75 |
| September 30, 2015 | -10.75 |
| June 30, 2015 | -15.50 |
| March 31, 2015 | -10.50 |
| December 31, 2014 | -16.75 |
| September 30, 2014 | -7.321 |
| June 30, 2014 | -4.728 |
| March 31, 2014 | -107.25 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 0.1822 |
| Alnylam Pharmaceuticals, Inc. | 1.207 |
| Savara, Inc. | -0.1587 |
| Vericel Corp. | 0.0422 |
| Biogen, Inc. | 0.6557 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -4.834M |
| Revenue (Quarterly) | 0.63M |
| Total Expenses (Quarterly) | 5.464M |
| Enterprise Value | 131.06M |
| Gross Profit Margin (Quarterly) | 69.68% |
| Profit Margin (Quarterly) | -767.3% |
| Earnings Yield | -14.75% |
| Normalized Earnings Yield | -13.10 |